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Abstract
Background: Although 18F- FDG PET/CT is validated in baseline workup of esophageal cancer to detect distant
metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to
evaluate the association between 18F- FDG PET/CT-derived parameters of esophageal cancer, and its clinico-pathological
features and prognosis.
Methods: All patients (n = 86) with esophageal adenocarcinoma or squamous cell cancer operated between 2005 and 2014
were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the
tumor’s maximal Standardized Uptake Value (SUVmax), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC
curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3/4) status,
long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses.
Results: High baseline SUVmax was associated with cT3/4 status and middle-third tumor location, TLG with a cT3/4 and cN+
status, whereas MTV only with active smoking. A cT3/4 status was significantly predicted by a SUVmax > 8.25 g/mL
(p < 0.001), TLG > 41.7 (p < 0.001) and MTV > 10.70 cm3 (p < 0.01) whereas a SUVmax > 12.7 g/mL was associated
with an early tumor recurrence and a poor disease-free survival (median 13 versus 56months, p = 0.030), particularly in
squamous cell cancer.
Conclusions: Baseline 18F- FDG PET/CT has a high predictive value of preoperative cT stage, as its parameters SUVmax,
TLG and MTV can predict a locally advanced tumor with high accuracy. A SUVmax > 12.7 g/mL may herald early tumor
recurrence and poor disease-free survival.
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Background
Esophageal cancer is associated with aggressive lymphatic
spread, resulting often in locally advanced or metastatic
disease upon diagnosis [1]. Metabolic imaging with 18F-
Fluorodeoxyglucose Positron Emission Tomography/
Computerized Tomography (18F- FDG -PET/CT) has
been integrated into the preoperative workup of esopha-
geal cancer for the detection of distant suspicions lesions
[1–3], interval metastases [4] or assessment of response to
neoadjuvant treatment [5]. Esophageal cancer workup
should use three-modality staging with Computerized
Tomography (CT), endoscopic ultrasound (EUS) and 18F-
FDG PET/CT [2, 3], as failure to identify locally advanced
tumors (cT3/4 or N+) may lead to omission of neoadju-
vant treatment before surgery, compromising patient sur-
vival [2, 6]. To this day, 18F- FDG PET/CT is not primarily
used for local staging of the primary tumor due to its poor
spatial resolution. However, Malik et al. recently demon-
strated a significant predictive value of Metabolic Tumor
Volume (MTV) in differentiating early-stage (cT1/2) from
locally advanced (cT3/4) lesions [7]. Obtaining accurate
cTN staging information through 18F- FDG PET/CT may
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be of prime importance particularly in cases where EUS is
unavailable or if the tumor is obstructive (up to 19% of pa-
tients) [7]. Furthermore, although the predictive value of
18F- FDG PET/CT derived parameters maximal standard-
ized Uptake Value (SUVmax), Total Lesion Glycolysis
(TLG) and MTV on long-term survival of esophageal can-
cer has been extensively reported in the literature [8], the
absence of universally accepted thresholds and the paucity
of data for each histological type limit the predictive value
for the individual patient.
The aim of our study was to assess the clinico-
pathological correlations and staging value of 18F- FDG
PET/CT derived parameters SUVmax, TLG and MTV, as
well as their predictive value in patient survival and
tumor recurrence.
Methods
All patients operated for esophageal adenocarcinoma or
squamous cell cancer, with curative intent, from 2005 to
2014 in our tertiary referral center and a baseline 18F- FDG
PET/CT in the preoperative workup were included in this
study. Demographic, clinical and histological data were re-
trieved from our prospectively maintained database.
In all patients, routine preoperative staging was
performed by esophagogastroduodenoscopy, EUS and
thoraco-abdominal CT scan. Since 2005 18F- FDG PET/
CT was integrated in the baseline preoperative workup,
according to current recommendations [2]. TNM stage
was defined according to the 7th TNM classification [9].
Neoadjuvant treatment was administered for locally ad-
vanced lesions (cT3/4 and/or N+), with 5FU-platin or
carboplatin-paclitaxel based chemotherapy and external
beam radiation of 41–54 Gy. R0 resection was defined as
the presence of tumor within 1mm of resection margins.
Postoperative follow-up included a thoraco-abdominal
CT scan every 4 months for the first two postoperative
years and further workup in cases of suspected recur-
rence [10]. Early recurrence was defined as any docu-
mented recurrence in the first 12 postoperative months.
Follow-up data were last updated in November 2018, to
assure a minimum follow-up of 4 years for all patients.
Baseline 18F- FDG PET/CT and derived parameters
Since the beginning of this study, we introduced our
own PET/quality control program used in several na-
tional and international PET studies [11] until our center
participated to the quality control program by the Euro-
pean Association of Nuclear Medicine (EANM)- EARL
as PET/CT Center of Excellence in October 2011, for
which we have been accredited each year so far. For 18F-
FDG PET/CT, patients fasted for at least 6 h before and
blood glucose was measured before administration of
the radiotracer and required to be < 8.5 mmol/L, other-
wise the scan was rescheduled. Each patient received 5.5
MBq/kg until 08/2011 or 3.5MBq/kg thereafter of 18F-
FDG intravenously and remained in a calm and warm
area for 1 h post injection. Thereafter, the patient was
asked to void and subsequently was placed in the scan-
ner. Images were acquired on PET/CT scanner (Discov-
ery LS until 08/2011 and thereafter Discovery D690
TOF; GE Healthcare, Waukesha, WI) with scatter and
point-spread function recovery corrections. The CT scan
(140 kV, 80 mA pith 1.5 until 08/2011 and thereafter
120 keV, 80–200 AutomA/SmartmA, pitch 1.375) was
used for attenuation correction. The CT scan was
followed by a PET over the same body region (3–5 min/
bed position acquired in 2-D mode until 08/2011 there-
after 1 min 30 s–2 min/bed position acquired in 3-D
mode). Images were reconstructed using OSEM (2 itera-
tions, 26 subsets) with a 5.4-mm FWHM post-filter and
3.91-mm FWHM loop filter until 08/2011 and thereafter
using OSEM (3 iterations, 16 subsets) with 5-mm post-
filter and PSF and TOF recovery corrections. Two nu-
clear medicine physicians (AP, JOP) closely reviewed the
images using for analysis an Advantage Workstation
(version 4.6, GE Healthcare, Waukesha, WI) using PET
VCAR software to compute SUVmean, SUVmax, TLG and
MTV.
SUVmax was defined as the point of maximal radio-
tracer uptake value within the delineated tumor volume
(g/mL). MTV represents the metabolically active volume
of the main tumor (cm3), whereas TLG was computed
as the product of MTV multiplied by the tumor’s SUV-
mean. In order to define the contouring margin of pri-
mary tumor, a volume of interest around the tumor was
drawn carefully to incorporate the target lesion in trans-
axial, sagittal and coronal planes. For tumor delineation
we used a 42% threshold, as it is the most commonly
used in the literature [7, 12].
Statistical analysis
Linear regression was performed to assess correlation
between several clinicopathological variables and base-
line SUVmax, TLG and MTV. For each PET/CT derived
parameter, a Receiver Operating Characteristic (ROC)
curve analysis was performed to assess whether an opti-
mal cutoff could be associated with locally advanced le-
sions (cT3/4), overall survival and early tumor
recurrence. Overall and disease-free survival were ana-
lyzed with the Kaplan-Meier method and log-rank test
as well as and a Cox regression analysis. Based on previ-
ously published differences in FDG uptake between
adenocarcinoma and squamous cell cancer [3, 13], sub-
group analyses were separately carried out for each
histological type. Co-variates with a p-value< 0.2 on a
univariate level were entered to a backward elimination
process, allowing to build the final multivariate model
with the lowest Akaike Information Criterion (AIC)
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value. Significance level was set at p < 0.05 and all tests
were two-sided. Statistical analysis was performed with
RStudio (version 3.2.3, RStudio Team 2015, Boston,
USA) and SPSS (version 23.0, Chicago, USA).
Results
From the 141 patients operated in the study period, 89
had a baseline 18F- FDG PET/CT in their workup (63%).
Three of them were excluded from analysis because of
histology other than adenocarcinoma or squamous cell;
thus, the current series consists of 86 patients. Baseline
patient characteristics are outlined in Table 1. Adenocar-
cinoma represented 53% and squamous cell histology 47%
of all lesions; 94% of all tumors were FDG-avid in 18F-
FDG PET/CT.
Baseline 18F- FDG PET/CT -derived parameters and initial
tumor staging
SUVmax (maximal standardized uptake value)
Median baseline SUVmax was 12.1 g/mL (range 2.8–48.0)
for all tumors. Middle third tumor location, advanced
cT and cN stage as well as squamous cell histology were
associated with higher SUVmax values on a univariate
level, however only tumor location and cT stage
remained significant on multiple regression (Table 2).
cT3/4 tumors had an expected SUVmax 6.61 higher than
a cT1–2 lesion (β coefficient 6.61, 95%CI 2.40, 10.81,
p = 0.002), and middle third tumors an expected SUVmax
7.01 higher than GEJ lesions (β coefficient 7.01, 95%CI
0.71–13.32, p = 0.029). The multivariable model pre-
sented a good fit to the data (R2 = 0.2804, F-statistic
4.676 on 6 and 72 DF, p < 0.0001).
Baseline SUVmax presented a good prognostic value of
a cT3/4 status in ROC curve analysis (Fig. 1a). A SUV-
max > 8.25 g/mL predicted a cT3/4 lesion with a sensitiv-
ity of 84% and a specificity of 68%. Overall accuracy as
indicated by the area under the curve (AUC) was 82%
(AUC = 0.816, 95%CI = 0.704–0.928, p < 0.001).
TLG (Total lesion glycolysis)
Median TLG for all tumors was 122.1 (range 1–1179).
Simple linear regression revealed higher TLG values for
cT3/4 and cN+ tumors, and both co-variates remained
significant in multivariate analysis; expected TLG for cT3/
4 tumors was 162.9 higher than cT1/2 tumors (β coeffi-
cient 162.95, 95% CI 31.39–294.51, p = 0.016), and cN+
had a TLG 145.83 higher than cN0 lesions (β coefficient
145.83, 95% 34.47–256.19, p = 0.010). (Table 3) The
model presented a good fit to the data (R2 = 0.1852, F-
statistic 7.841 on 2 and 69DF, p < 0.001).
ROC curve analysis identified a TLG > 41.7 g as the
optimal cutoff to detect a cT3/4 lesion, with a sensi-
tivity of 86%, a specificity of 80% and an overall
accuracy of 85% (AUC 0.852, 95%CI 0.744–0.960, p <
0.001) (Fig. 1b).
MTV (metabolic tumor volume)
Median MTV for all FDG-avid tumors was 22.7 cm3 (range
1–519). Univariate analysis identified only active smoking be-
ing associated with higher baseline MTV (β coefficient 32.81,
95%CI 4.99–70.62, p = 0.093) and thus, no multivariable ana-
lysis was possible for this parameter.
Table 1 Baseline demographics and preoperative workup of all
patients
Variable N = 86
Median age, years [range] 63 [38–82]
Male Gender (%) 66 (77)





Upper third 3 (4)
Middle third 27 (31)
Distal third 29 (34)
Gastroesophageal junction 27 (31)
Clinical T stage (cT)
cT1–2 21 (24)
cT3–4 63 (73)
Missing data 2 (2)
Clinical N stage (cN)
cN0 33 (38)
cN+ 49 (57)
Missing data 4 (5)
Tumor histology
Adenocarcinoma 46 (53)




EUS non-obstructive lesion 73 (85)
18F- FDG PET/CT 86 (100)
18F- FDG PET/CT -avid lesion 81 (94)
Neoadjuvant treatment 71 (82)
Operative approach
Transthoracic (Lewis) 65 (76)
Three-field (McKeown) 19 (22)
Transhiatal 2 (2)
ASA American Society of Anesthesiology, CT Computerized tomography, EUS
Endoscopic ultrasound, 18F- FDG PET/CT 18F-Fluorodeoxyglucose Positron
Emission Tomography CT
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In ROC curve analysis a baseline MTV > 10.70 cm3
was identified as the optimal cutoff to predict cT3/4 sta-
tus (sensitivity 83.1%; specificity 75%, AUC 0.799, 95%CI
0.640–0.959, p = 0.01) (Fig. 1c).
Prognostic value of 18F- FDG PET/CT -derived parameters
for recurrence and patient survival
Among the three parameters studied, SUVmax at baseline
was the only one with a significant predictive value for
early tumor recurrence, within the 1st postoperative year
(Fig. 2). A SUVmax > 12.7 g/mL predicted early recur-
rence with 70.4% sensitivity and 64.6% specificity (AUC
0.660, 95% CI 0.535–0.785, p = 0.019) (Fig. 2a). Patients
with a SUVmax ≤ 12.7 g/mL at baseline had a median
disease-free survival (DFS) of 56 months (95%CI 7.7–
104), versus 13 (95%CI 10.4–15.7) for those with a SUV-
max > 12.7 g/mL (p = 0.030) (Fig. 3). Cox regression con-
firmed SUVmax > 12.7 g/mL as an independent predictor
of DFS (HR 2.54, 95%CI 1.26, 5.09, p = 0.009), along
with preoperative active smoking and pT3/4 status
(Table 4).
When the two histological subtypes were analyzed sep-
arately, there was no significant association of SUVmax
with DFS for adenocarcinoma. For squamous cell carcin-
oma, a baseline SUVmax > 12.7 g/mL along with pT and
pN stage independently predicted worse DFS (Table 4).
Table 2 Linear regression analysis for baseline SUVmax
Variable Unadjusted β coefficient 95%CI P-value Adjusted β coefficient 95%CI P-value
cT stage
cT1–2 Ref Ref
cT3–4 7.76 3.64,11.87 < 0.001 6.61 2.40,10.81 0.002
cN stage
cN0 Ref Ref
cN+ 4.12 0.29,7.95 0.038 3.28 −0.49,7.05 0.087
Tumor location
GEJ Ref Ref
Distal third 1.41 −2.99,5.80 0.53 1.59 −3.10,6.29 0.50
Middle third 6.27 1.80,10.75 0.007 7.01 0.71,13.32 0.029
Superior third −1.42 −11.26,8.42 0.78 −1.47 −12.05,9.11 0.78
Histology
Adenocarcinoma Ref
Squamous cell 3.84 0.23,7.45 0.040 −0.630 −5.84,4.58 0.81
SUVmax Maximal standardized uptake value, GEJ Gastroesophageal junction, 95%CI 95% confidence intervals, Ref Reference category (β coefficient = 0)
Fig. 1 ROC curve analyses for the predictive value of 18FDG-PET/CT derived parameters in relation to a cT3/4 status. All three parameters
predicted significantly cT3–4 status of the primary tumor. a SUVmax > 8.25 g/mL (sensitivity 83.9%, specificity 68.4%, p < 0.001), b TLG > 41.7 g
(sensitivity 86.4%, specificity 80%, p < 0.001), c MTV > 10.7 cm3 (sensitivity 83.1%, specificity 75%, p = 0.01)
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The distinct metabolic profile of the two histological
types is illustrated in Fig. 4.
No association was found between baseline SUVmax
and overall survival (OS), neither on the Kaplan-Meier
(Fig. 3) nor the Cox regression analysis. In the latter,
only active smoking (HR 2.30, 95% CI 1.15–4.62, p =
0.019) and pT4 stage (HR 21.42, 95%CI 5.00–91.72, p <
0.0001) independently predicted OS. None of the vari-
ables remained independent predictors of OS in adeno-
carcinoma or squamous cell subtypes.
Median follow-up of all patients, calculated with the
reverse Kaplan-Meier method, was 50 months (95%CI
45.33–54.66).
Discussion
In this study, higher baseline SUVmax of esophageal can-
cer was significantly related to a middle-third tumor lo-
cation and a cT3/4 stage, whereas higher TLG was
related to cT3/4 and cN+ stage. Baseline SUVmax > 8.25
g/mL, TLG > 41.7 and MTV > 10.7 cm3 were associated
with cT/4 stage, whereas SUVmax ≥ 12.7 g/mL predicted
early recurrence and poor disease-free survival.
Currently, 18F- FDG PET/CT is mostly used for the
detection of distant metastases as it can identify
suspicious lesions as small as 1 cm [2, 14, 15]. Walker
et al. reported 18F- FDG PET/CT -detected distant le-
sions precluding curative treatment in 21% of patients
[15], even though the specificity of an FDG ‘hot spot’ re-
mains low [16]. Until recently, limited spatial resolution
of PET for esophageal wall layers and adjacent structures
had restrained this modality as a detector of distant
metastases [15]. Recent data, however, reinforce the
role of 18F- FDG PET/CT in better defining cTNM
stage and the tumor’s biology, the latter being FDG-
avid in 84–92% of cases especially if it infiltrates the
submucosa [7, 15, 17].
It is generally admitted that all 18F- FDG PET/CT-de-
rived parameters are higher in advanced and aggressive
tumors, however no universally accepted cutoffs exist to
this day, limiting their cTNM staging value in the
individual patient. Malik et al. suggested SUVmax > 4.1
(sensitivity 85%, and specificity 48%) and MTV > 23.4
cm3 (sensitivity 64%, specificity 67%) as optimal thresh-
olds to distinguish cT1/2 from cT3/4 lesions [7]. In our
study, SUVmax and TLG presented a higher predictive
value than MTV in preoperative staging; ROC curve
analysis yielded as significant cutoff values to predict
preoperative cT3/4 status with high accuracy a SUVmax >
Table 3 Linear regression analysis for baseline TLG
Variable Unadjusted β coefficient 95%CI P-value Adjusted β coefficient 95%CI P-value
cT stage
cT1–2 Ref Ref
cT3–4 198.42 61.42,335.43 0.006 162.95 31.39,294.51 0.016
cN stage
cN0 Ref Ref
cN+ 168.77 58.05,279.48 0.004 145.83 35.47,256.19 0.010
TLG Total lesion glycolysis, 95%CI 95% confidence intervals, Ref Reference category (β coefficient = 0)
Fig. 2 ROC curve analyses for 18FDG-PET/CT derived parameters as predictors of early tumor recurrence. a A SUVmax > 12.7 g/mL was identified as
the optimal threshold for early recurrence, with a sensitivity of 70.4%, specificity 63.6% (AUC 0.660, p = 0.019). No optimal cutoff was defined for b
TLG (AUC 0.624, 95% CI 0.495–0.753, p = 0.081) or c MTV (AUC 0.570, 95%CI 0.431–0.709, p = 0.332)
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8.25 g/mL, TLG > 41.7 and MTV > 10.70 cm3. This dis-
crepancy may be explained by the predominance of
adenocarcinoma in the Malik study (75% of patients,
versus 53% in the present study); adenocarcinoma has
being described as less FDG-avid with lower SUVmax
values compared to squamous cell cancer, probably in
relation to increased expression of the HK-II biomarker
[3, 13]. However, as in our study tumor histology was
not independently associated with SUVmax (Table 2), no
separate cutoffs of SUVmax were justified for each type.
One might argue that EUS is sufficient to identify lo-
cally advanced lesions (cT3/4 or N+) and thus to direct
the patient to neoadjuvant treatment before surgery.
However, previous data from our institution suggest a
rather low rate of accurate usT (51%) and usN (72%) sta-
ging, with the highest rates of understaging among active
smokers [18]. Indeed, a three-modality workup strategy
(18F- FDG PET/CT, CT and EUS) offers the highest
probability (84%) to correctly select patients for surgery,
a fortiori when 18F- FDG PET/CT is the first exam per-
formed [3]. Complementary use of these exams could
improve staging accuracy, directing patients with locally
advanced lesions to neoadjuvant treatment and avoiding
its unnecessary toxicity for early-stage tumors.
Although several studies have reported poor long-term
prognosis associated with high baseline SUVmax its prog-
nostic value for the individual patient remains limited, as
great variability is seen in the suggested cutoffs (ranging
from 3 to 9 g/mL) [16, 19–22]. This variability might be
linked to patient-related factors (e.g. cardiac output,
tumor histology) but also to the PET/CT configuration
and interobserver variability. To overcome these limita-
tions, tumor-to-blood Standard Uptake Ratio (SUR) has
been recently published as a promising predictor of sur-
vival [23, 24]. Hofheinz et al. [23] suggest the superiority
of baseline SUR over SUVmax to predict overall survival
in squamous cell cancer patients treated with definitive
chemoradiation, whereas Bütof et al. [24] propose the re-
staging SUR value along with baseline MTV as a reliable
survival predictor. In a recent meta-analysis, Han et al.
reinforce the prognostic value of MTV and TLG for
overall survival, although no specific cutoff value is sug-
gested and both histological types are jointly taken into
account [8]. In the present study none of the 18F- FDG
PET/CT derived parameters demonstrated significant as-
sociation with overall survival.
The added value of our study lies in the identification
of SUVmax > 12.7 g/mL as an independent predictor of
early tumor recurrence, within the 1st postoperative
year. This result is of major clinical importance, as it
might help early identification of patients with resectable
esophageal cancer, who may not benefit from surgical
resection as their risk of short-term recurrence is signifi-
cantly increased. Indeed, we observed a significantly
shorter DFS for squamous cell tumors with a baseline
SUVmax > 12.7 g/mL; as definitive chemoradiation is a
valid treatment option for this histological type, the
above threshold may provide valuable prognostic infor-
mation for the individual patient and guide accordingly
therapeutic management. Schreurs et al. previously re-
ported worse DFS for patients with baseline SUVmax >
3.67 g/mL, although no correlation with overall survival
was found in that study either [3]. Markers of aggressive
biology (GLUT-1, p53, Ki-67, HK-II) were studied in re-
lation to SUVmax, although no clear immunohistochemi-
cal profile was found for high-FDG uptake tumors
Fig. 3 Baseline SUVmax as a predictor of disease-free and overall postoperative survival. a SUVmax > 12.7 g/mL was a significant predictor of poor
disease-free survival (median DFS 13 versus 56months, p = 0.030), b but not of overall survival
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compared to the others [3]. Thus, even though it is gen-
erally admitted that high baseline SUVmax may herald
tumor aggressiveness and early recurrence, the under-
lying mechanism remains poorly understood. Our team
previously reported active smoking as an independent
predictor of early recurrence after esophagectomy [25],
which is being confirmed in the present analysis along
with a baseline SUVmax > 12.7 g/mL, and may express
Table 4 Cox regression analysis for disease-free survival (DFS)
Variable Unadjusted HR 95%CI P-value Adjusted HR 95%CI P-value
All patients
Active smoking 2.22 1.23,4.01 0.008 2.22 1.15,4.27 0.017
SUVmax> 12.7 g/mL 2.10 1.16,3.81 0.014 2.54 1.26,5.09 0.009
pT stage
pT0 Ref Ref
pT1 0.30 0.06,1.45 0.135 0.59 0.11,3.04 0.532
pT2 1.32 0.49,3.57 0.577 1.55 0.56,4.28 0.393
pT3 2.78 1.18,6.55 0.019 3.31 1.37,8.00 0.008
pT4 11.93 2.25,63.29 0.004 7.24 1.34,39.22 0.022
Resection margins
R0 Ref
R+ 2.47 1.04,5.89 0.041 2.09 0.77,5.68 0.147
Adenocarcinoma
Active smoking 2.34 1.04–5.28 0.039 2.54 1.05–6.14 0.039
SUVmax> 12.7 g/mL 1.87 0.85–4.11 0.119 1.54 0.65–3.62 0.323
pN stage
pN0 Ref Ref
pN1 5.76 2.06–16.09 < 0.001 4.04 1.29–12.58 0.016
pN2 5.24 1.78–15.49 0.003 3.88 1.25–12.02 0.019
pN3 9.31 1.82–47.49 0.007 8.67 1.50–50.07 0.016
Resection margins
R0 Ref




cT3–4 2.74 0.92–8.10 0.069 0.96 0.19–4.78 0.961
SUVmax> 12.7 g/mL 1.82 0.76–4.36 0.176 5.06 1.44–17.71 0.011
pT stage
pT0 Ref Ref
pT1 0.84 0.16–4.33 0.833 1.23 0.21–7.17 0.816
pT2 1.95 0.56–6.76 0.290 5.67 1.34–24.01 0.018
pT3 5.97 1.95–18.29 0.002 5.05 1.10–23.16 0.037
pT4 11.75 1.17–118.29 0.037 10.67 0.93–122.39 0.057
pN stage
pN0 Ref Ref
pN1 0.22 0.03–1.67 0.144 0.09 0.01–0.92 0.042
pN2 4.51 1.42–14.31 0.010 4.71 1.00–22.14 0.049
pN3 4.39 0.95–20.32 0.058 6.72 0.90–49.88 0.062
HR Hazard ratio, 95%CI 95% confidence intervals, Ref Reference category, SUVmax Maximal standardized uptake value
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pathologic DNA-methylation patterns and tumor prolif-
eration genes [26].
This study has some limitations that need to be ad-
dressed. Retrospective analysis has an inherent drawback
in data completeness, even though our institutional data-
base is maintained prospectively, with a stringent follow-
up of all patients. The use of two different PET/CT
scanners over the years might have introduce some bias
in SUVmax measurements especially in the smaller-
volume lesions, because of a better resolution recovery
in the newer PET/CT scanner (from September 2011
and thereafter). However, both scanners measured simi-
lar SUV for lesions above 1.2 cm diameter (about 4 cm3).
Since the mean MTV in our series was well above this
threshold (48 cm3 ± 83 cm3), it can be estimated that this
scanner change had little effect on the results. Moreover,
we compared the SUVmax across both scanners in le-
sions with a MTV ≥30 cm3 (where SUVmax would be
similar with both scanners) vs. lesions < 30 cm3, where
the new scanner could measure SUVmax better. No dif-
ferences were observed across scanners in the large le-
sions (MTV ≥ 30 cm3: SUVmax 20.6 ± 7.8 g/mL for the
new scanner vs. 17.3 ± 12.0 g/mL for the previous one,
p = 0.36). This was also the case for the smaller lesions
(MTV < 30 cm3: SUVmax 9.9 ± 4.9 g/mL for the new
scanner vs. 11.9 ± 4.4 g/mL for the previous one, p =
0.17). Results of this comparative analysis between the
two CT scans are provided as supplementary material,
and enhance our belief that the scanner change could
not influence significantly our results.
Although there was practically no heterogeneity in 18F-
FDG PET/CT results over the years, inaccuracies in the
preoperative workup may have occurred for both T and N
staging especially with EUS, confounding associations with
18F- FDG PET/CT parameters. As mentioned above,
histological type and patient-related factors may influence
18F- FDG PET/CT-derived parameters and limit the use
of universally accepted cutoffs. In the present study, due
to the small number of patients per histological type our
subgroup analyses can be considered as exploratory, need-
ing validation in larger cohorts. Prospective validation of
the suggested cutoffs should take into account the speci-
ficities of histological types studied.
Conclusions
18F- FDG PET/CT derived parameters SUVmax > 8.25 g/
mL, TLG > 41.7 g and MTV > 10.70 cm3 were signifi-
cantly associated with locally advanced cT3/4 stage and
a baseline SUVmax > 12.7 g/mL with early tumor recur-
rence and poor disease-free survival, particularly for
squamous cell cancer. These findings add to the existing
knowledge of 18F- FDG PET/CT’s value in esophageal cancer
Fig. 4 Axial and coronal 18−FDG PET/CT fusion images of two distinct esophageal malignancies with different metabolic profiles. Illustration of the
distinct metabolic profile a cT1N0 adenocarcinoma of the gastroesophageal junction (Panels a and b, SUVmax = 5.5, TLG = 5) versus a cT3N+
squamous cell middle third lesion (Panels c and d, SUVmax = 12.8, TLG = 311.5). The white arrows show the primary tumor hypercaptation in
each image
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management and reinforce its predictive value in terms of
tumor recurrence and survival. A prospective study is cur-
rently running in our institution to correlate these values
with high-resolution CT and MR imaging characteristics of
the primary tumor.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12880-019-0401-x.
Additional file 1. Comparison of the SUVmax values for large
(MTV>=30cm3) and small (MTV<30cm3) tumors, for the two CT
scanners used in the study.
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